Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Subscribe To Our Newsletter & Stay Updated
